Revance Therapeutics Inc.
www.revance.com
Latest From Revance Therapeutics Inc.
Mylan Still Mulling Revance's Botox Biosimilar
Revance says it is still in discussions with Mylan on whether or not the pair will proceed with their collaboration on a biosimilar version of Botox, despite an extended deadline for a commitment on the deal having passed on 30 April.
Coronavirus Update: Vertex, Pfizer And Others Disclose Trial Disruptions, Viatris Merger Delayed
Clinical trials in a range of diseases continue to be impacted by concerns about patient safety and health care resources as the COVID-19 pandemic grows.
Revance Awaits Mylan Decision On Botox Biosimilar
Revance Therapeutics is evaluating its options for developing a biosimilar version of Allergan’s globally renowned Botox cosmetic brand, as it waits for Mylan to decide whether to press on with the opportunity or opt out, per terms agreed last August.
Finance Watch: Biopharma Stocks See Big Post-IPO Jumps
Public Company Edition: Five out of six drug developers and a CRO have seen their values spike immediately after going public this month. Also, Moderna floats a $500m offering, Revance proposes a $20m note sale, and Nestle invests another $200m in Aimmune.
Company Information
- Industry
-
Biotechnology
- Large Molecule
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
- Site Specific
- Topical Delivery
-
Drug Delivery
- Therapeutic Areas
- Dermatology
- Gynecological, Urological
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Alias(es)
- Essentia Biosystems Inc.
- Ownership
- Public
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Revance Therapeutics Inc.
- Senior Management
-
Mark J Foley, Pres. & CEO
Tobin Schilke, CFO
Abhay Joshi, PhD, COO
Taryn Conway, VP, Mktg. - Contact Info
-
Revance Therapeutics Inc.
Phone: (510) 742-3400
7555 Gateway Blvd.
Newark, CA 94560
USA